Hazzard W R, Kushwaha R S, Applebaum-Bowden D, Haffner S M, Steinmetz A, Foster D M
Metabolism. 1984 Oct;33(10):873-81. doi: 10.1016/0026-0495(84)90239-7.
Studies of simultaneous autologous 131I-chylomicron (Sf greater than 400) and 125I-very low density lipoprotein (VLDL) (Sf 20 to 400) apolipoprotein B (apo B) were performed both before (triglyceride level c 1500 mg/dL) and during treatment with stanozolol, a 17 alpha-methyl anabolic androgenic steroid (triglyceride level c 750 mg/dL) in a 74-year-old woman with a past history of recurrent chylomicronemic pancreatitis. Both before and during stanozolol treatment chylomicron apo B disappeared rapidly and directly, little appearing in VLDL and virtually none in intermediate (IDL) or low density lipoproteins (LDL). Multicompartmental analysis indicated that the great majority of chylomicron apo B was removed via an extremely rapid compartment (estimated fractional catabolic rate [FCR], 5.0/h), accounting for 66% before and 88% during stanozolol treatment. The remaining 131I-apo B decayed biphasically, with total Sf greater than 400 residence times of 8.6 hours before and 3.7 hours during stanozolol treatment. Hence, despite a moderately depressed adipose tissue lipoprotein lipase activity, the subject's hypertriglyceridemia did not appear to proceed solely from retarded chylomicron removal, nor was the dramatic decrease in triglyceride in response to stanozolol a function only of the acceleration of such removal. VLDL apo B kinetics were analyzed by a multicompartmental model featuring a rapid, stepwise delipidation chain which proceeds either rapidly to IDL and LDL or to a slowly turning over compartment within VLDL. While VLDL. apo B synthesis remained essentially constant, the major effect of stanozolol was a substantial reduction in the fraction of VLDL apo B diverted to this slowly turning over compartment, which decreased from 5.0% before to 1.2% during treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
对一名有复发性乳糜微粒血症性胰腺炎病史的74岁女性,在使用司坦唑醇(一种17α-甲基合成代谢雄激素类固醇)治疗前(甘油三酯水平约1500mg/dL)和治疗期间(甘油三酯水平约750mg/dL),进行了同时自体131I-乳糜微粒(Sf大于400)和125I-极低密度脂蛋白(VLDL)(Sf 20至400)载脂蛋白B(apo B)的研究。在司坦唑醇治疗前后,乳糜微粒apo B均迅速直接消失,很少出现在VLDL中,在中间密度脂蛋白(IDL)或低密度脂蛋白(LDL)中几乎没有。多室分析表明,绝大多数乳糜微粒apo B通过一个极快速的室被清除(估计分解代谢率[FCR]为5.0/小时),在司坦唑醇治疗前占66%,治疗期间占88%。其余的131I-apo B呈双相衰变,司坦唑醇治疗前总Sf大于400的停留时间为8.6小时,治疗期间为3.7小时。因此,尽管脂肪组织脂蛋白脂肪酶活性中度降低,但该受试者的高甘油三酯血症似乎并非仅由乳糜微粒清除延迟所致,司坦唑醇治疗后甘油三酯的显著降低也不仅仅是由于这种清除加速。VLDL apo B动力学通过一个多室模型进行分析,该模型具有一个快速的逐步脱脂链,该链要么迅速转变为IDL和LDL,要么转变为VLDL内一个周转缓慢的室。虽然VLDL apo B合成基本保持不变,但司坦唑醇的主要作用是大幅降低转向这个周转缓慢的室的VLDL apo B比例,该比例从治疗前的5.0%降至治疗期间的1.2%。(摘要截短于250字)